Edward Discoe, MD
Family Medicine · Columbus, NENPI 1447252721
Payments from drug & device makers
Across 137 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$368
- Amgen$346
- AbbVie$283
- Novo Nordisk$191
- Lilly USA, LLC$159
- Pfizer$85
- plus $697 from 25 others
What the payments were for
- Food & beverage$2,123100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $368 |
| Amgen | 27 | $346 |
| AbbVie(2 entities) | 29 | $283 |
| Novo Nordisk | 15 | $191 |
| Lilly USA, LLC | 8 | $159 |
| Pfizer | 6 | $85 |
| Johnson & Johnson(2 entities) | 6 | $77 |
| Abbott | 4 | $76 |
| Boehringer Ingelheim | 5 | $71 |
| Xeris Pharmaceuticals, Inc. | 3 | $57 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $49 |
| GSK | 3 | $38 |
| Astellas Pharma US Inc | 1 | $28 |
| Amarin Pharma, Inc. | 2 | $28 |
| Merck | 2 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Medicure Pharma Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Baxter Healthcare | 1 | $14 |
| Mylan Specialty L.p. | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Novartis | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Bayer | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,129 in reported general payments places this provider in the 75th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 177 | $197,219 |
| OzempicSemaglutide | 110 | $145,460 |
| JardianceEmpagliflozin | 121 | $133,107 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 109 | $77,557 |
| TrulicityDulaglutide | 47 | $66,454 |
| XareltoRivaroxaban | 70 | $58,684 |
| Repatha SureclickEvolocumab | 61 | $57,314 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $40,607 |
| MounjaroTirzepatide | 36 | $35,669 |
| Repatha SyringeEvolocumab | 26 | $30,083 |
| Praluent PenAlirocumab | 20 | $24,152 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $18,806 |
| FarxigaDapagliflozin Propanediol | 19 | $17,826 |
| MyrbetriqMirabegron | 30 | $15,005 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $13,953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $85 | $197,219177 claims |
| Novo NordiskOzempic, Rybelsus | $191 | $156,354122 claims |
| Boehringer IngelheimJardiance | $71 | $133,107121 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix | $38 | $105,297181 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $159 | $102,12383 claims |
| Johnson & JohnsonXarelto | $77 | $58,68470 claims |
| AstraZenecaFarxiga | $368 | $17,82619 claims |
| Astellas Pharma US IncMyrbetriq | $28 | $15,00530 claims |
| AbbVieSynthroid | $283 | $5,51251 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Columbus
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.